Literature DB >> 21402910

High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells.

Jewel Daniel1, Jonathan Coulter, Ju-Hyung Woo, Kathleen Wilsbach, Edward Gabrielson.   

Abstract

Most human cancers are aneuploid and have chromosomal instability, which contrasts to the inability of human cells to normally tolerate aneuploidy. Noting that aneuploidy in human breast cancer correlates with increased expression levels of the Mps1 checkpoint gene, we investigated whether these high levels of Mps1 contribute to the ability of breast cancer cells to tolerate this aneuploidy. Reducing Mps1 levels in cultured human breast cancer cells by RNAi resulted in aberrant mitoses, induction of apoptosis, and decreased ability of human breast cancer cells to grow as xenografts in nude mice. Remarkably, breast cancer cells that survive reductions in levels of Mps1 have relatively less aneuploidy, as measured by copies of specific chromosomes, compared with cells that have constitutively high levels of Mps1. Thus, high levels of Mps1 in breast cancer cells likely contribute to these cells tolerating aneuploidy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402910      PMCID: PMC3069188          DOI: 10.1073/pnas.1007645108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation.

Authors:  Celia Vogel; Christian Hager; Holger Bastians
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

2.  Mad2 overexpression promotes aneuploidy and tumorigenesis in mice.

Authors:  Rocío Sotillo; Eva Hernando; Elena Díaz-Rodríguez; Julie Teruya-Feldstein; Carlos Cordón-Cardo; Scott W Lowe; Robert Benezra
Journal:  Cancer Cell       Date:  2006-12-28       Impact factor: 31.743

3.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

4.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.

Authors:  Anna V Ivshina; Joshy George; Oleg Senko; Benjamin Mow; Thomas C Putti; Johanna Smeds; Thomas Lindahl; Yudi Pawitan; Per Hall; Hans Nordgren; John E L Wong; Edison T Liu; Jonas Bergh; Vladimir A Kuznetsov; Lance D Miller
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

5.  Mps1 phosphorylates Borealin to control Aurora B activity and chromosome alignment.

Authors:  Nannette Jelluma; Arjan B Brenkman; Niels J F van den Broek; Carin W A Cruijsen; Maria H J van Osch; Susanne M A Lens; René H Medema; Geert J P L Kops
Journal:  Cell       Date:  2008-01-25       Impact factor: 41.582

6.  The genomic landscapes of human breast and colorectal cancers.

Authors:  Laura D Wood; D Williams Parsons; Siân Jones; Jimmy Lin; Tobias Sjöblom; Rebecca J Leary; Dong Shen; Simina M Boca; Thomas Barber; Janine Ptak; Natalie Silliman; Steve Szabo; Zoltan Dezso; Vadim Ustyanksky; Tatiana Nikolskaya; Yuri Nikolsky; Rachel Karchin; Paul A Wilson; Joshua S Kaminker; Zemin Zhang; Randal Croshaw; Joseph Willis; Dawn Dawson; Michail Shipitsin; James K V Willson; Saraswati Sukumar; Kornelia Polyak; Ben Ho Park; Charit L Pethiyagoda; P V Krishna Pant; Dennis G Ballinger; Andrew B Sparks; James Hartigan; Douglas R Smith; Erick Suh; Nickolas Papadopoulos; Phillip Buckhaults; Sanford D Markowitz; Giovanni Parmigiani; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein
Journal:  Science       Date:  2007-10-11       Impact factor: 47.728

7.  Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

Authors:  Charles Swanton; Michela Marani; Olivier Pardo; Patricia H Warne; Gavin Kelly; Erik Sahai; Frédéric Elustondo; Jenny Chang; Jillian Temple; Ahmed A Ahmed; James D Brenton; Julian Downward; Barbara Nicke
Journal:  Cancer Cell       Date:  2007-06       Impact factor: 31.743

8.  Examining the link between chromosomal instability and aneuploidy in human cells.

Authors:  Sarah L Thompson; Duane A Compton
Journal:  J Cell Biol       Date:  2008-02-18       Impact factor: 10.539

9.  High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.

Authors:  Suet F Chin; Andrew E Teschendorff; John C Marioni; Yanzhong Wang; Nuno L Barbosa-Morais; Natalie P Thorne; Jose L Costa; Sarah E Pinder; Mark A van de Wiel; Andrew R Green; Ian O Ellis; Peggy L Porter; Simon Tavaré; James D Brenton; Bauke Ylstra; Carlos Caldas
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

10.  Mps1 kinase promotes sister-kinetochore bi-orientation by a tension-dependent mechanism.

Authors:  Jean-François Maure; Etsushi Kitamura; Tomoyuki U Tanaka
Journal:  Curr Biol       Date:  2007-11-29       Impact factor: 10.834

View more
  62 in total

1.  Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.

Authors:  Yong Liu; Radoslaw Laufer; Narendra Kumar Patel; Grace Ng; Peter B Sampson; Sze-Wan Li; Yunhui Lang; Miklos Feher; Richard Brokx; Irina Beletskaya; Richard Hodgson; Olga Plotnikova; Donald E Awrey; Wei Qiu; Nickolay Y Chirgadze; Jacqueline M Mason; Xin Wei; Dan Chi-Chia Lin; Yi Che; Reza Kiarash; Graham C Fletcher; Tak W Mak; Mark R Bray; Henry W Pauls
Journal:  ACS Med Chem Lett       Date:  2016-05-06       Impact factor: 4.345

2.  Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.

Authors:  Uday Bhanu Maachani; Tamalee Kramp; Ryan Hanson; Shuping Zhao; Orieta Celiku; Uma Shankavaram; Riccardo Colombo; Natasha J Caplen; Kevin Camphausen; Anita Tandle
Journal:  Mol Cancer Res       Date:  2015-02-26       Impact factor: 5.852

3.  Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.

Authors:  Jacqueline M Mason; Xin Wei; Graham C Fletcher; Reza Kiarash; Richard Brokx; Richard Hodgson; Irina Beletskaya; Mark R Bray; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-07       Impact factor: 11.205

4.  Phenotypic, structural, and ultrastructural analysis of triple-negative breast cancer cell lines and breast cancer stem cell subpopulation.

Authors:  Milene Pereira Moreira; Fábio André Brayner; Luiz Carlos Alves; Geovanni Dantas Cassali; Luciana Maria Silva
Journal:  Eur Biophys J       Date:  2019-09-04       Impact factor: 1.733

5.  Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation.

Authors:  Ken-Ichi Kusakabe; Nobuyuki Ide; Yataro Daigo; Takeshi Itoh; Kenichi Higashino; Yousuke Okano; Genta Tadano; Yuki Tachibana; Yuji Sato; Makiko Inoue; Tooru Wada; Motofumi Iguchi; Takayuki Kanazawa; Yukichi Ishioka; Keiji Dohi; Sachie Tagashira; Yasuto Kido; Shingo Sakamoto; Kazuya Yasuo; Masahiro Maeda; Takahiko Yamamoto; Masayo Higaki; Takeshi Endoh; Kazuo Ueda; Takeshi Shiota; Hitoshi Murai; Yusuke Nakamura
Journal:  ACS Med Chem Lett       Date:  2012-06-06       Impact factor: 4.345

Review 6.  The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers.

Authors:  Qingli Jiao; Aiguo Wu; Guoli Shao; Haoyu Peng; Mengchuan Wang; Shufeng Ji; Peng Liu; Jian Zhang
Journal:  J Thorac Dis       Date:  2014-09       Impact factor: 2.895

7.  Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.

Authors:  Roger B Slee; Brenda R Grimes; Ruchi Bansal; Jesse Gore; Corinne Blackburn; Lyndsey Brown; Rachel Gasaway; Jaesik Jeong; Jose Victorino; Keith L March; Riccardo Colombo; Brittney-Shea Herbert; Murray Korc
Journal:  Mol Cancer Ther       Date:  2013-11-26       Impact factor: 6.261

Review 8.  Targeting the cell cycle in breast cancer: towards the next phase.

Authors:  K L Thu; I Soria-Bretones; T W Mak; D W Cescon
Journal:  Cell Cycle       Date:  2018-09-11       Impact factor: 4.534

9.  TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.

Authors:  Balázs Győrffy; Giulia Bottai; Jacqueline Lehmann-Che; György Kéri; László Orfi; Takayuki Iwamoto; Christine Desmedt; Giampaolo Bianchini; Nicholas C Turner; Hugues de Thè; Fabrice André; Christos Sotiriou; Gabriel N Hortobagyi; Angelo Di Leo; Lajos Pusztai; Libero Santarpia
Journal:  Mol Oncol       Date:  2014-01-05       Impact factor: 6.603

10.  The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition.

Authors:  Erik Fredlund; Johan Staaf; Juha K Rantala; Olli Kallioniemi; Ake Borg; Markus Ringnér
Journal:  Breast Cancer Res       Date:  2012-07-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.